25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Kolon Life Science Inc
Buy, Hold or Sell?

Let's analyze Kolon Life Science Inc together

I guess you are interested in Kolon Life Science Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Kolon Life Science Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Kolon Life Science Inc

I send you an email if I find something interesting about Kolon Life Science Inc.

1. Quick Overview

1.1. Quick analysis of Kolon Life Science Inc (30 sec.)










1.2. What can you expect buying and holding a share of Kolon Life Science Inc? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
10.3%

What is your share worth?

Current worth
₩10,361.31
Expected worth in 1 year
₩6,558.71
How sure are you?
37.9%

+ What do you gain per year?

Total Gains per Share
₩-3,802.60
Return On Investment
-20.2%

For what price can you sell your share?

Current Price per Share
₩18,870.00
Expected price per share
₩16,780 - ₩20,000
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Kolon Life Science Inc (5 min.)




Live pricePrice per Share (EOD)
₩18,870.00

2.2. Growth of Kolon Life Science Inc (5 min.)




Is Kolon Life Science Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$89.4m$104.6m-$3.8m-3.8%

How much money is Kolon Life Science Inc making?

Current yearPrevious yearGrowGrow %
Making money-$14.7m-$1.8m-$12.9m-87.7%
Net Profit Margin-56.2%-8.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Kolon Life Science Inc (5 min.)




2.4. Comparing to competitors in the Pharmaceuticals industry (5 min.)




  Industry Rankings (Pharmaceuticals)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Kolon Life Science Inc?

Welcome investor! Kolon Life Science Inc's management wants to use your money to grow the business. In return you get a share of Kolon Life Science Inc.

First you should know what it really means to hold a share of Kolon Life Science Inc. And how you can make/lose money.

Speculation

The Price per Share of Kolon Life Science Inc is ₩18,870. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Kolon Life Science Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Kolon Life Science Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩10,361.31. Based on the TTM, the Book Value Change Per Share is ₩-950.65 per quarter. Based on the YOY, the Book Value Change Per Share is ₩1,308.35 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Kolon Life Science Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-3.370.0%-1.220.0%-0.160.0%-0.460.0%-0.590.0%
Usd Book Value Change Per Share-2.540.0%-0.670.0%0.920.0%-0.030.0%0.250.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-2.540.0%-0.670.0%0.920.0%-0.030.0%0.250.0%
Usd Price Per Share14.46-16.70-22.92-19.85-33.40-
Price to Earnings Ratio-1.07--7.89-13.65--6.63--11.54-
Price-to-Total Gains Ratio-5.69--10.91-181.94--20.78--72.86-
Price to Book Ratio1.99-1.94-2.68-3.29-3.20-
Price-to-Total Gains Ratio-5.69--10.91-181.94--20.78--72.86-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share13.209
Number of shares75
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.67-0.03
Usd Total Gains Per Share-0.67-0.03
Gains per Quarter (75 shares)-49.91-2.20
Gains per Year (75 shares)-199.64-8.79
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-200-2100-9-19
20-399-4100-18-28
30-599-6100-26-37
40-799-8100-35-46
50-998-10100-44-55
60-1198-12100-53-64
70-1397-14100-61-73
80-1597-16100-70-82
90-1797-18100-79-91
100-1996-20100-88-100

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%3.09.00.025.0%5.015.00.025.0%6.023.00.020.7%6.023.00.020.7%
Book Value Change Per Share1.03.00.025.0%6.06.00.050.0%8.012.00.040.0%11.018.00.037.9%11.018.00.037.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%3.00.026.010.3%3.00.026.010.3%
Total Gains per Share1.03.00.025.0%6.06.00.050.0%8.012.00.040.0%11.018.00.037.9%11.018.00.037.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Kolon Life Science Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---3631.423-950.650-74%1308.354-378%-41.836-99%357.287-1116%
Book Value Per Share--10361.31012404.567-16%13095.093-21%9704.750+7%17277.794-40%
Current Ratio--0.6240.796-22%0.993-37%0.855-27%1.195-48%
Debt To Asset Ratio--0.6410.566+13%0.511+26%0.611+5%0.514+25%
Debt To Equity Ratio--1.7891.331+34%1.066+68%1.743+3%1.351+32%
Dividend Per Share----0%-0%-0%4.596-100%
Eps---4809.827-1749.548-64%-226.637-95%-650.230-86%-838.047-83%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap215272734000.000-18%254644979400.000276929647600.000-8%373612135500.000-32%324460048220.000-22%545004730628.090-53%
Net Profit Margin---1.481-0.562-62%-0.082-94%-0.294-80%-0.331-78%
Operating Margin----0%0.002-100%-0.0130%-0.0630%
Operating Ratio--1.8342.014-9%1.510+21%1.348+36%1.557+18%
Pb Ratio1.821-9%1.9931.935+3%2.681-26%3.292-39%3.201-38%
Pe Ratio-0.981+9%-1.073-7.886+635%13.648-108%-6.627+517%-11.538+975%
Price Per Share18870.000-9%20650.00023850.000-13%32737.500-37%28352.500-27%47712.069-57%
Price To Free Cash Flow Ratio----4.8640%-3.7150%-13.9910%-15.5350%
Price To Total Gains Ratio-5.196+9%-5.686-10.911+92%181.943-103%-20.777+265%-72.860+1181%
Quick Ratio---0.151-100%0.353-100%0.346-100%0.384-100%
Return On Assets---0.166-0.061-63%-0.008-95%-0.025-85%-0.027-84%
Return On Equity---0.464-0.159-66%-0.015-97%-0.076-84%-0.070-85%
Total Gains Per Share---3631.423-950.650-74%1308.354-378%-41.836-99%361.883-1103%
Usd Book Value--89439172.900100762310.469-11%104612142.212-15%77850223.231+15%138217770.392-35%
Usd Book Value Change Per Share---2.542-0.665-74%0.916-378%-0.029-99%0.250-1116%
Usd Book Value Per Share--7.2538.683-16%9.167-21%6.793+7%12.094-40%
Usd Dividend Per Share----0%-0%-0%0.003-100%
Usd Eps---3.367-1.225-64%-0.159-95%-0.455-86%-0.587-83%
Usd Free Cash Flow----6246772.0370%-4086643.1150%-6119751.7460%-6355440.7610%
Usd Market Cap150690913.800-18%178251485.580193850753.320-8%261528494.850-32%227122033.754-22%381503311.440-53%
Usd Price Per Share13.209-9%14.45516.695-13%22.916-37%19.847-27%33.398-57%
Usd Profit---41518586.200-14750165.957-64%-1810525.568-96%-5348417.394-87%-6799903.568-84%
Usd Revenue--28031845.80024547797.766+14%27513519.791+2%26916312.763+4%25689276.359+9%
Usd Total Gains Per Share---2.542-0.665-74%0.916-378%-0.029-99%0.253-1103%
 EOD+3 -4MRQTTM+4 -22YOY+4 -235Y+7 -1910Y+4 -24

3.3 Fundamental Score

Let's check the fundamental score of Kolon Life Science Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.981
Price to Book Ratio (EOD)Between0-11.821
Net Profit Margin (MRQ)Greater than0-1.481
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than10.624
Debt to Asset Ratio (MRQ)Less than10.641
Debt to Equity Ratio (MRQ)Less than11.789
Return on Equity (MRQ)Greater than0.15-0.464
Return on Assets (MRQ)Greater than0.05-0.166
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Kolon Life Science Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.365
Ma 20Greater thanMa 5018,216.500
Ma 50Greater thanMa 10018,697.600
Ma 100Greater thanMa 20020,202.800
OpenGreater thanClose18,300.000
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Kolon Life Science Inc

Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for anti-cancer and intermediates; and pyrithione antimicrobial for shampoo and soap bars, cosmetic and wet wipes, fabric softeners, metalworking fluids, antifouling paints, and fire-fighters. In addition, it offers Kolon BESFLOC polymer used in chemical, food, leather, pharmaceutical, textile, and dairy industries, as well as in settling reservoirs, sludge thickeners, floating reservoirs, and dehydrators in sewage treatment plants. The company was formerly known as Korea Tissuegene Asia, Ltd. and changed its name to Kolon Life Science Inc. in January 2006. Kolon Life Science Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-11-19 00:11:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Kolon Life Science Inc earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Kolon Life Science Inc to the Pharmaceuticals industry mean.
  • A Net Profit Margin of -148.1% means that ₩-1.48 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Kolon Life Science Inc:

  • The MRQ is -148.1%. The company is making a huge loss. -2
  • The TTM is -56.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-148.1%TTM-56.2%-91.9%
TTM-56.2%YOY-8.2%-48.0%
TTM-56.2%5Y-29.4%-26.8%
5Y-29.4%10Y-33.1%+3.6%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-148.1%9.8%-157.9%
TTM-56.2%9.5%-65.7%
YOY-8.2%9.9%-18.1%
5Y-29.4%12.9%-42.3%
10Y-33.1%12.6%-45.7%
4.3.1.2. Return on Assets

Shows how efficient Kolon Life Science Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Kolon Life Science Inc to the Pharmaceuticals industry mean.
  • -16.6% Return on Assets means that Kolon Life Science Inc generated ₩-0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Kolon Life Science Inc:

  • The MRQ is -16.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.6%TTM-6.1%-10.5%
TTM-6.1%YOY-0.8%-5.3%
TTM-6.1%5Y-2.5%-3.6%
5Y-2.5%10Y-2.7%+0.2%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.6%3.6%-20.2%
TTM-6.1%3.5%-9.6%
YOY-0.8%5.3%-6.1%
5Y-2.5%5.9%-8.4%
10Y-2.7%4.9%-7.6%
4.3.1.3. Return on Equity

Shows how efficient Kolon Life Science Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Kolon Life Science Inc to the Pharmaceuticals industry mean.
  • -46.4% Return on Equity means Kolon Life Science Inc generated ₩-0.46 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Kolon Life Science Inc:

  • The MRQ is -46.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -15.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-46.4%TTM-15.9%-30.5%
TTM-15.9%YOY-1.5%-14.4%
TTM-15.9%5Y-7.6%-8.4%
5Y-7.6%10Y-7.0%-0.5%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-46.4%4.6%-51.0%
TTM-15.9%4.6%-20.5%
YOY-1.5%8.2%-9.7%
5Y-7.6%9.1%-16.7%
10Y-7.0%10.3%-17.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Kolon Life Science Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Kolon Life Science Inc is operating .

  • Measures how much profit Kolon Life Science Inc makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Kolon Life Science Inc to the Pharmaceuticals industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Kolon Life Science Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY0.2%-0.2%
TTM-5Y-1.3%+1.3%
5Y-1.3%10Y-6.3%+4.9%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.2%-13.2%
TTM-12.0%-12.0%
YOY0.2%12.4%-12.2%
5Y-1.3%8.6%-9.9%
10Y-6.3%12.1%-18.4%
4.3.2.2. Operating Ratio

Measures how efficient Kolon Life Science Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • An Operation Ratio of 1.83 means that the operating costs are ₩1.83 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Kolon Life Science Inc:

  • The MRQ is 1.834. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.014. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.834TTM2.014-0.180
TTM2.014YOY1.510+0.503
TTM2.0145Y1.348+0.666
5Y1.34810Y1.557-0.209
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8341.225+0.609
TTM2.0141.220+0.794
YOY1.5101.311+0.199
5Y1.3481.249+0.099
10Y1.5571.240+0.317
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Kolon Life Science Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Kolon Life Science Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A Current Ratio of 0.62 means the company has ₩0.62 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Kolon Life Science Inc:

  • The MRQ is 0.624. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.796. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.624TTM0.796-0.173
TTM0.796YOY0.993-0.196
TTM0.7965Y0.855-0.059
5Y0.85510Y1.195-0.340
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6242.213-1.589
TTM0.7962.234-1.438
YOY0.9932.028-1.035
5Y0.8552.199-1.344
10Y1.1951.995-0.800
4.4.3.2. Quick Ratio

Measures if Kolon Life Science Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Kolon Life Science Inc to the Pharmaceuticals industry mean.
  • A Quick Ratio of 0.00 means the company can pay off ₩0.00 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Kolon Life Science Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.151-0.151
TTM0.151YOY0.353-0.202
TTM0.1515Y0.346-0.196
5Y0.34610Y0.384-0.038
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.926-0.926
TTM0.1510.973-0.822
YOY0.3531.515-1.162
5Y0.3461.591-1.245
10Y0.3841.399-1.015
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Kolon Life Science Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Kolon Life Science Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Kolon Life Science Inc to Pharmaceuticals industry mean.
  • A Debt to Asset Ratio of 0.64 means that Kolon Life Science Inc assets are financed with 64.1% credit (debt) and the remaining percentage (100% - 64.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Kolon Life Science Inc:

  • The MRQ is 0.641. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.566. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.641TTM0.566+0.076
TTM0.566YOY0.511+0.055
TTM0.5665Y0.611-0.045
5Y0.61110Y0.514+0.097
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6410.345+0.296
TTM0.5660.339+0.227
YOY0.5110.333+0.178
5Y0.6110.315+0.296
10Y0.5140.339+0.175
4.5.4.2. Debt to Equity Ratio

Measures if Kolon Life Science Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Kolon Life Science Inc to the Pharmaceuticals industry mean.
  • A Debt to Equity ratio of 178.9% means that company has ₩1.79 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Kolon Life Science Inc:

  • The MRQ is 1.789. The company is just able to pay all its debts with equity.
  • The TTM is 1.331. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.789TTM1.331+0.458
TTM1.331YOY1.066+0.264
TTM1.3315Y1.743-0.413
5Y1.74310Y1.351+0.392
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7890.547+1.242
TTM1.3310.547+0.784
YOY1.0660.499+0.567
5Y1.7430.476+1.267
10Y1.3510.548+0.803
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Kolon Life Science Inc generates.

  • Above 15 is considered overpriced but always compare Kolon Life Science Inc to the Pharmaceuticals industry mean.
  • A PE ratio of -1.07 means the investor is paying ₩-1.07 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Kolon Life Science Inc:

  • The EOD is -0.981. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.073. Based on the earnings, the company is expensive. -2
  • The TTM is -7.886. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.981MRQ-1.073+0.093
MRQ-1.073TTM-7.886+6.813
TTM-7.886YOY13.648-21.534
TTM-7.8865Y-6.627-1.259
5Y-6.62710Y-11.538+4.912
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD-0.98128.107-29.088
MRQ-1.07329.844-30.917
TTM-7.88627.532-35.418
YOY13.64823.102-9.454
5Y-6.62727.577-34.204
10Y-11.53829.248-40.786
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Kolon Life Science Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-4.864+4.864
TTM-4.864YOY-3.715-1.149
TTM-4.8645Y-13.991+9.127
5Y-13.99110Y-15.535+1.544
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.531-29.531
TTM-4.86429.447-34.311
YOY-3.71526.360-30.075
5Y-13.99131.734-45.725
10Y-15.53534.357-49.892
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Kolon Life Science Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A PB ratio of 1.99 means the investor is paying ₩1.99 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Kolon Life Science Inc:

  • The EOD is 1.821. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.993. Based on the equity, the company is underpriced. +1
  • The TTM is 1.935. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.821MRQ1.993-0.172
MRQ1.993TTM1.935+0.058
TTM1.935YOY2.681-0.746
TTM1.9355Y3.292-1.357
5Y3.29210Y3.201+0.091
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD1.8214.674-2.853
MRQ1.9933.381-1.388
TTM1.9353.209-1.274
YOY2.6812.597+0.084
5Y3.2923.278+0.014
10Y3.2014.179-0.978
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-06-302023-09-302023-12-312024-03-312024-06-30
Operating Income  -4,477,982-1,081,328-5,559,310-2,763,124-8,322,4345,532,121-2,790,3136,111,7593,321,446



6.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets356,355,086
Total Liabilities228,584,839
Total Stockholder Equity127,770,247
 As reported
Total Liabilities 228,584,839
Total Stockholder Equity+ 127,770,247
Total Assets = 356,355,086

Assets

Total Assets356,355,086
Total Current Assets114,189,089
Long-term Assets242,165,997
Total Current Assets
Total Current Assets  (as reported)114,189,089
Total Current Assets  (calculated)0
+/- 114,189,089
Long-term Assets
Long-term Assets  (as reported)242,165,997
Long-term Assets  (calculated)0
+/- 242,165,997

Liabilities & Shareholders' Equity

Total Current Liabilities183,040,532
Long-term Liabilities45,544,307
Total Stockholder Equity127,770,247
Total Current Liabilities
Total Current Liabilities  (as reported)183,040,532
Total Current Liabilities  (calculated)0
+/- 183,040,532
Long-term Liabilities
Long-term Liabilities  (as reported)45,544,307
Long-term Liabilities  (calculated)0
+/- 45,544,307
Total Stockholder Equity
Total Stockholder Equity (as reported)127,770,247
Total Stockholder Equity (calculated)0
+/- 127,770,247
Other
Common Stock Shares Outstanding 12,331
Net Invested Capital 127,770,247
Net Working Capital -68,851,443



6.3. Balance Sheets Structured

Currency in KRW. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302013-09-302013-06-30
> Total Assets 
0
0
338,151,648
336,622,017
716,796,713
687,195,783
614,019,594
699,401,829
618,903,273
561,836,745
313,871,610
303,127,853
278,294,781
266,984,393
273,466,002
246,001,671
248,337,694
284,902,406
243,492,473
238,308,020
234,658,307
226,254,444
246,925,213
250,140,804
314,117,887
316,352,407
330,422,772
314,828,008
309,435,551
350,701,711
356,355,086
356,355,086350,701,711309,435,551314,828,008330,422,772316,352,407314,117,887250,140,804246,925,213226,254,444234,658,307238,308,020243,492,473284,902,406248,337,694246,001,671273,466,002266,984,393278,294,781303,127,853313,871,610561,836,745618,903,273699,401,829614,019,594687,195,783716,796,713336,622,017338,151,64800
   > Total Current Assets 
87,184,700
82,617,010
169,369,319
165,403,765
150,975,687
139,668,013
135,557,053
130,506,821
105,716,540
106,258,672
109,310,767
101,882,673
91,159,916
88,010,229
95,310,216
96,090,997
100,563,064
138,964,127
99,771,099
96,567,651
98,020,933
90,705,632
111,417,541
115,142,394
110,184,254
109,838,280
121,087,233
109,079,467
105,045,244
113,562,339
114,189,089
114,189,089113,562,339105,045,244109,079,467121,087,233109,838,280110,184,254115,142,394111,417,54190,705,63298,020,93396,567,65199,771,099138,964,127100,563,06496,090,99795,310,21688,010,22991,159,916101,882,673109,310,767106,258,672105,716,540130,506,821135,557,053139,668,013150,975,687165,403,765169,369,31982,617,01087,184,700
       Cash And Cash Equivalents 
0
0
99,987,288
90,446,570
55,825,058
42,644,261
41,956,386
32,695,689
32,671,369
34,826,193
20,174,699
16,418,470
5,913,523
8,786,150
15,292,452
14,060,757
15,000,810
52,898,275
26,069,379
23,975,074
27,800,285
0
0
0
6,371,342
6,834,277
26,046,144
11,412,638
7,561,343
8,386,709
0
08,386,7097,561,34311,412,63826,046,1446,834,2776,371,34200027,800,28523,975,07426,069,37952,898,27515,000,81014,060,75715,292,4528,786,1505,913,52316,418,47020,174,69934,826,19332,671,36932,695,68941,956,38642,644,26155,825,05890,446,57099,987,28800
       Short-term Investments 
0
0
3,111,414
3,000,000
23,000,000
20,000,000
15,100,000
20,100,000
5,100,000
100,000
15,000,000
15,000,000
15,000,000
0
0
30,000
30,000
0
110,000
110,000
110,000
110,000
0
0
0
0
0
0
0
0
0
000000000110,000110,000110,000110,000030,00030,0000015,000,00015,000,00015,000,000100,0005,100,00020,100,00015,100,00020,000,00023,000,0003,000,0003,111,41400
       Net Receivables 
25,278,201
24,328,025
20,076,992
20,485,656
21,694,343
19,481,064
21,725,473
21,331,543
24,528,850
22,571,454
24,921,722
20,734,246
29,457,396
24,374,012
23,075,401
25,637,598
22,199,037
24,804,934
22,178,865
22,879,699
20,286,888
20,003,133
36,283,099
38,300,543
29,584,010
27,294,883
23,526,751
21,936,087
24,604,535
31,426,834
0
031,426,83424,604,53521,936,08723,526,75127,294,88329,584,01038,300,54336,283,09920,003,13320,286,88822,879,69922,178,86524,804,93422,199,03725,637,59823,075,40124,374,01229,457,39620,734,24624,921,72222,571,45424,528,85021,331,54321,725,47319,481,06421,694,34320,485,65620,076,99224,328,02525,278,201
       Inventory 
34,820,693
38,484,432
43,182,486
48,311,949
46,531,505
53,387,563
50,037,568
50,751,886
37,427,098
39,819,480
38,826,993
40,795,314
36,063,861
36,836,557
40,774,962
42,653,998
42,790,379
45,380,249
47,788,799
46,412,495
45,998,025
50,493,323
55,976,887
65,802,681
68,493,646
69,481,331
66,249,800
70,746,094
67,777,281
67,231,147
0
067,231,14767,777,28170,746,09466,249,80069,481,33168,493,64665,802,68155,976,88750,493,32345,998,02546,412,49547,788,79945,380,24942,790,37942,653,99840,774,96236,836,55736,063,86140,795,31438,826,99339,819,48037,427,09850,751,88650,037,56853,387,56346,531,50548,311,94943,182,48638,484,43234,820,693
       Other Current Assets 
254,976
1,119,300
109,523
438,920
455,269
1,106,878
3,450,569
2,371,009
2,994,520
5,063,482
7,246,223
2,040
284,204
175,590
12,647,243
12,731,243
12,350,440
12,427,444
106,668
312,131
82,570
645,971
1,744,190
1,252,889
15,000
15,000
96,090
250
1
0
0
00125096,09015,00015,0001,252,8891,744,190645,97182,570312,131106,66812,427,44412,350,44012,731,24312,647,243175,590284,2042,0407,246,2235,063,4822,994,5202,371,0093,450,5691,106,878455,269438,920109,5231,119,300254,976
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
203,933,633
206,514,128
209,335,539
205,748,542
204,390,307
237,139,372
242,165,997
242,165,997237,139,372204,390,307205,748,542209,335,539206,514,128203,933,633000000000000000000000000
       Property Plant Equipment 
110,231,039
109,513,801
135,362,669
136,825,763
144,248,746
151,762,592
155,657,564
163,912,154
166,350,076
175,140,140
179,746,813
180,239,256
178,398,040
174,432,737
147,695,345
144,781,234
141,893,424
140,000,800
138,215,964
137,404,688
131,480,754
130,423,375
130,405,572
129,894,790
125,960,014
125,778,829
127,057,986
128,386,601
123,137,635
123,212,003
0
0123,212,003123,137,635128,386,601127,057,986125,778,829125,960,014129,894,790130,405,572130,423,375131,480,754137,404,688138,215,964140,000,800141,893,424144,781,234147,695,345174,432,737178,398,040180,239,256179,746,813175,140,140166,350,076163,912,154155,657,564151,762,592144,248,746136,825,763135,362,669109,513,801110,231,039
       Goodwill 
0
0
2,992,403
2,992,403
2,992,403
2,992,403
2,992,403
2,992,403
1,894,369
1,894,369
1,894,369
1,894,369
1,216,705
1,216,705
1,216,705
1,216,705
1,216,705
1,216,705
1,216,705
1,216,705
1,216,705
1,216,705
1,216,705
1,216,705
1,216,705
0
0
0
0
0
0
0000001,216,7051,216,7051,216,7051,216,7051,216,7051,216,7051,216,7051,216,7051,216,7051,216,7051,216,7051,216,7051,216,7051,894,3691,894,3691,894,3691,894,3692,992,4032,992,4032,992,4032,992,4032,992,4032,992,40300
       Long Term Investments 
0
0
14,548,332
15,048,332
400,522,930
374,937,008
298,760,451
380,016,097
336,195,385
269,242,400
14,088,797
12,776,829
2,142,979
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000002,142,97912,776,82914,088,797269,242,400336,195,385380,016,097298,760,451374,937,008400,522,93015,048,33214,548,33200
       Intangible Assets 
0
0
2,964,055
2,950,997
17,140,251
7,873,909
7,771,531
7,896,261
7,376,750
7,231,541
6,893,076
5,985,698
900,392
844,994
789,959
1,288,673
722,221
666,261
610,588
555,975
502,147
461,255
419,803
377,790
342,591
307,392
273,408
318,115
332,530
297,867
0
0297,867332,530318,115273,408307,392342,591377,790419,803461,255502,147555,975610,588666,261722,2211,288,673789,959844,994900,3925,985,6986,893,0767,231,5417,376,7507,896,2617,771,5317,873,90917,140,2512,950,9972,964,05500
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
0
-1
-1
0
0
00-1-100-1000000000000000000000000
> Total Liabilities 
0
0
78,970,011
78,368,809
171,384,499
163,815,217
149,994,138
180,931,980
172,757,459
202,582,142
186,122,275
185,049,051
177,274,348
168,916,484
180,280,857
149,574,133
190,380,561
227,118,600
179,241,623
172,558,400
135,248,150
129,380,046
145,007,213
147,787,219
146,394,638
150,289,214
168,779,130
164,175,647
171,763,576
191,011,665
228,584,839
228,584,839191,011,665171,763,576164,175,647168,779,130150,289,214146,394,638147,787,219145,007,213129,380,046135,248,150172,558,400179,241,623227,118,600190,380,561149,574,133180,280,857168,916,484177,274,348185,049,051186,122,275202,582,142172,757,459180,931,980149,994,138163,815,217171,384,49978,368,80978,970,01100
   > Total Current Liabilities 
57,129,275
42,843,121
57,588,976
57,544,764
63,056,024
64,003,986
70,551,466
73,575,179
77,009,485
97,783,708
107,709,229
120,888,274
126,173,394
117,659,045
128,771,718
103,433,032
145,152,196
182,169,806
135,981,074
129,880,491
95,469,232
91,236,238
109,800,605
112,210,361
109,577,507
111,905,008
126,482,472
116,246,191
128,341,446
141,054,409
183,040,532
183,040,532141,054,409128,341,446116,246,191126,482,472111,905,008109,577,507112,210,361109,800,60591,236,23895,469,232129,880,491135,981,074182,169,806145,152,196103,433,032128,771,718117,659,045126,173,394120,888,274107,709,22997,783,70877,009,48573,575,17970,551,46664,003,98663,056,02457,544,76457,588,97642,843,12157,129,275
       Short-term Debt 
0
0
52,936,434
27,393,500
8,232,760
8,857,040
8,387,040
7,949,540
7,512,040
7,074,540
6,637,040
48,187,938
53,742,332
49,600,703
50,567,927
66,200,898
61,751,285
104,568,806
99,906,454
97,687,488
59,064,347
57,794,791
64,194,440
72,293,568
69,461,334
76,380,616
97,498,521
0
0
0
0
000097,498,52176,380,61669,461,33472,293,56864,194,44057,794,79159,064,34797,687,48899,906,454104,568,80661,751,28566,200,89850,567,92749,600,70353,742,33248,187,9386,637,0407,074,5407,512,0407,949,5408,387,0408,857,0408,232,76027,393,50052,936,43400
       Short Long Term Debt 
0
0
52,936,434
27,393,500
8,232,760
8,857,040
8,387,040
7,949,540
7,512,040
7,074,540
6,637,040
6,632,040
6,520,410
0
0
0
0
0
0
0
0
0
0
0
73,461,324
79,047,276
98,831,851
87,570,471
97,262,377
112,757,195
0
0112,757,19597,262,37787,570,47198,831,85179,047,27673,461,324000000000006,520,4106,632,0406,637,0407,074,5407,512,0407,949,5408,387,0408,857,0408,232,76027,393,50052,936,43400
       Accounts payable 
16,423,961
12,912,494
9,090,625
9,911,890
11,701,244
12,175,303
12,080,623
11,815,820
10,267,691
13,764,314
13,875,915
9,345,676
10,714,297
11,447,244
13,246,783
11,979,426
0
12,440,934
14,134,454
10,961,603
13,773,950
12,742,093
22,139,875
20,774,427
17,049,209
16,087,103
10,725,448
10,787,381
11,547,093
12,989,539
0
012,989,53911,547,09310,787,38110,725,44816,087,10317,049,20920,774,42722,139,87512,742,09313,773,95010,961,60314,134,45412,440,934011,979,42613,246,78311,447,24410,714,2979,345,67613,875,91513,764,31410,267,69111,815,82012,080,62312,175,30311,701,2449,911,8909,090,62512,912,49416,423,961
       Other Current Liabilities 
2,379,966
2,558,268
6,704,259
6,787,257
11,104,598
13,177,949
17,679,855
19,993,485
24,346,390
44,773,544
41,986,673
53,996,502
53,064,833
47,635,982
53,579,640
16,793,345
0
57,244,199
13,439,675
12,827,506
13,816,351
12,187,419
14,589,941
9,865,681
0
0
1
1
0
-1
0
0-1011009,865,68114,589,94112,187,41913,816,35112,827,50613,439,67557,244,199016,793,34553,579,64047,635,98253,064,83353,996,50241,986,67344,773,54424,346,39019,993,48517,679,85513,177,94911,104,5986,787,2576,704,2592,558,2682,379,966
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
36,817,131
38,384,206
42,296,658
47,929,456
43,422,130
49,957,256
45,544,307
45,544,30749,957,25643,422,13047,929,45642,296,65838,384,20636,817,131000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
19,835,710
18,237,351
16,680,574
15,403,565
10,992,072
9,595,456
8,277,118
6,909,751
5,590,818
4,191,010
2,862,189
1,499,252
222,179
167,183
222,330
5,311,307
0
0
0
0
00005,311,307222,330167,183222,1791,499,2522,862,1894,191,0105,590,8186,909,7518,277,1189,595,45610,992,07215,403,56516,680,57418,237,35119,835,71000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
-52,936,434
-27,393,500
-8,232,760
-8,857,040
-8,387,040
-7,949,540
-7,512,040
-7,074,540
-6,637,040
-48,187,938
-53,742,332
-49,600,703
-50,567,927
-66,200,898
-61,751,285
-104,568,806
-99,906,454
-97,687,488
-59,064,347
-57,794,791
-64,194,440
-72,293,568
-69,006,527
-75,620,468
-96,483,879
827,019
619,994
771,860
0
0771,860619,994827,019-96,483,879-75,620,468-69,006,527-72,293,568-64,194,440-57,794,791-59,064,347-97,687,488-99,906,454-104,568,806-61,751,285-66,200,898-50,567,927-49,600,703-53,742,332-48,187,938-6,637,040-7,074,540-7,512,040-7,949,540-8,387,040-8,857,040-8,232,760-27,393,500-52,936,43400
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000
       Deferred Long Term Liability 
0
0
9,577,671
9,298,050
0
9,034,920
12,990,188
13,767,688
1,049,748
1,025,680
995,832
965,983
641,824
611,975
582,127
552,279
0
492,582
462,734
432,886
403,037
373,189
343,340
313,492
0
0
0
0
0
0
0
0000000313,492343,340373,189403,037432,886462,734492,5820552,279582,127611,975641,824965,983995,8321,025,6801,049,74813,767,68812,990,1889,034,92009,298,0509,577,67100
> Total Stockholder Equity
0
0
259,181,637
258,253,208
545,412,214
523,380,566
464,025,457
518,469,848
446,145,814
359,254,603
127,749,335
118,078,802
101,020,433
98,067,910
93,185,145
96,427,538
57,957,133
57,783,806
64,250,849
65,749,620
99,410,157
96,874,398
101,918,000
102,353,585
167,723,250
166,063,193
161,643,642
150,652,362
137,671,976
159,690,047
127,770,247
127,770,247159,690,047137,671,976150,652,362161,643,642166,063,193167,723,250102,353,585101,918,00096,874,39899,410,15765,749,62064,250,84957,783,80657,957,13396,427,53893,185,14598,067,910101,020,433118,078,802127,749,335359,254,603446,145,814518,469,848464,025,457523,380,566545,412,214258,253,208259,181,63700
   Common Stock
2,610,302
2,617,035
3,805,445
3,805,445
3,805,445
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
5,706,178
0
0
0
0
00005,706,1785,706,1785,706,1785,706,1785,706,1785,706,1785,706,1785,706,1785,706,1785,706,1785,706,1785,706,1785,706,1785,706,1785,706,1785,706,1785,706,1785,706,1785,706,1785,706,1785,706,1785,706,1783,805,4453,805,4453,805,4452,617,0352,610,302
   Retained Earnings Total Equity0000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
167,980,438
167,980,438
167,980,438
167,980,438
167,980,438
167,980,438
167,980,438
167,980,438
167,167,561
209,541,578
209,104,619
209,114,193
209,114,193
209,114,193
209,114,193
209,114,193
0
0
0
0
0000209,114,193209,114,193209,114,193209,114,193209,114,193209,104,619209,541,578167,167,561167,980,438167,980,438167,980,438167,980,438167,980,438167,980,438167,980,438167,980,43800000000000
   Treasury Stock0000000000-812,8770-812,877-812,877-812,877-812,877-812,877-812,877-812,877-812,87700000000000
   Other Stockholders Equity 
14,087
7,677
1
1
288,721,584
269,809,289
213,563,354
272,590,509
240,606,483
190,591,631
-1,174,898
-2,198,233
-10,492,636
-10,492,636
-10,492,636
-10,492,636
0
-10,463,177
-10,417,824
-9,663,696
-9,000,726
-9,000,725
-9,000,725
-9,000,725
0
0
0
0
0
0
0
0000000-9,000,725-9,000,725-9,000,725-9,000,726-9,663,696-10,417,824-10,463,1770-10,492,636-10,492,636-10,492,636-10,492,636-2,198,233-1,174,898190,591,631240,606,483272,590,509213,563,354269,809,289288,721,584117,67714,087



6.4. Balance Sheets

Currency in KRW. All numbers in thousands.




6.5. Cash Flows

Currency in KRW. All numbers in thousands.




6.6. Income Statements

Currency in KRW. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in KRW. All numbers in thousands.

Gross Profit (+$)
totalRevenue124,639,035
Cost of Revenue-112,227,855
Gross Profit12,411,18012,411,180
 
Operating Income (+$)
Gross Profit12,411,180
Operating Expense-148,774,374
Operating Income-24,135,339-136,363,194
 
Operating Expense (+$)
Research Development14,891,888
Selling General Administrative11,464,025
Selling And Marketing Expenses0
Operating Expense148,774,37426,355,913
 
Net Interest Income (+$)
Interest Income168,585
Interest Expense-5,857,166
Other Finance Cost-362,789
Net Interest Income-6,051,370
 
Pretax Income (+$)
Operating Income-24,135,339
Net Interest Income-6,051,370
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-33,598,114-24,135,339
EBIT - interestExpense = -5,857,166
-30,726,340
-24,869,174
Interest Expense5,857,166
Earnings Before Interest and Taxes (EBIT)0-27,740,948
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-33,598,114
Tax Provision-1,253
Net Income From Continuing Ops-33,599,367-33,599,367
Net Income-30,726,340
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net06,051,370
 

Technical Analysis of Kolon Life Science Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Kolon Life Science Inc. The general trend of Kolon Life Science Inc is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Kolon Life Science Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Kolon Life Science Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 19,690 < 19,930 < 20,000.

The bearish price targets are: 16,780.

Tweet this
Kolon Life Science Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Kolon Life Science Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Kolon Life Science Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Kolon Life Science Inc. The current macd is -174.82933924.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Kolon Life Science Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Kolon Life Science Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Kolon Life Science Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Kolon Life Science Inc Daily Moving Average Convergence/Divergence (MACD) ChartKolon Life Science Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Kolon Life Science Inc. The current adx is 14.98.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Kolon Life Science Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Kolon Life Science Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Kolon Life Science Inc. The current sar is 16,813.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Kolon Life Science Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Kolon Life Science Inc. The current rsi is 57.37. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Kolon Life Science Inc Daily Relative Strength Index (RSI) ChartKolon Life Science Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Kolon Life Science Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Kolon Life Science Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Kolon Life Science Inc Daily Stochastic Oscillator ChartKolon Life Science Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Kolon Life Science Inc. The current cci is 73.67.

Kolon Life Science Inc Daily Commodity Channel Index (CCI) ChartKolon Life Science Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Kolon Life Science Inc. The current cmo is 31.94.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Kolon Life Science Inc Daily Chande Momentum Oscillator (CMO) ChartKolon Life Science Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Kolon Life Science Inc. The current willr is -25.88652482.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Kolon Life Science Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Kolon Life Science Inc Daily Williams %R ChartKolon Life Science Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Kolon Life Science Inc.

Kolon Life Science Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Kolon Life Science Inc. The current atr is 716.04.

Kolon Life Science Inc Daily Average True Range (ATR) ChartKolon Life Science Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Kolon Life Science Inc. The current obv is 800,009.

Kolon Life Science Inc Daily On-Balance Volume (OBV) ChartKolon Life Science Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Kolon Life Science Inc. The current mfi is 64.34.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Kolon Life Science Inc Daily Money Flow Index (MFI) ChartKolon Life Science Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Kolon Life Science Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-07-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-07-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-07-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-08-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-29STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-09-13MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-11BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-10-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.

6.3. Candlestick Patterns

Kolon Life Science Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Kolon Life Science Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.365
Ma 20Greater thanMa 5018,216.500
Ma 50Greater thanMa 10018,697.600
Ma 100Greater thanMa 20020,202.800
OpenGreater thanClose18,300.000
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Kolon Life Science Inc with someone you think should read this too:
  • Are you bullish or bearish on Kolon Life Science Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Kolon Life Science Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Kolon Life Science Inc

I send you an email if I find something interesting about Kolon Life Science Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Kolon Life Science Inc.

Receive notifications about Kolon Life Science Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.